Globus Medical (NYSE:GMED) shares dipped today despite fourth-quarter results that came in ahead of the consensus forecast.

Globus Medical saw a strong 2024 with multiple new product launches and more innovation is on the way, President and CEO Dan Scavilla said in a Feb. 20 earnings ...

BTIG analyst Ryan Zimmerman raised the firm’s price target on Globus Medical (GMED) to $94 from $91 and keeps a Buy rating on the shares after ...

Wells Fargo analyst Vik Chopra lowered the firm’s price target on Globus Medical (GMED) to $93 from $95 and keeps an Overweight rating on the ...

Medical technologies specialist Globus Medical ( GMED 0.04%) reported impressive results for the fourth quarter of 2024 on Thursday, Feb. 20. The highlights included adjusted earnings per share (EPS) ...

Globus Medical (GMED) delivered earnings and revenue surprises of 10.53% and 2.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Globus Medical saw fourth quarter net sales grow 6.6% year over year, and full year sales leapt 60.6%, according to financial results posted Feb. 20.

Globus Medical expects full-year earnings in the range of $3.40 to $3.50 per share, with revenue in the range of $2.66 billion to $2.69 billion. This story was generated by Automated Insights ( http:/ ...

GMED earnings call for the period ending December 31, 2024.

Globus Medical Inc. (NYSE:GMED), a leading medical device company specializing in musculoskeletal disorders, has been making waves in the healthcare sector with its recent acquisition of Nevro Corp ...

Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...